42,066 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by World Investment Advisors LLC

World Investment Advisors LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 42,066 shares of the biopharmaceutical company's stock, valued at approximately $44,221,000. Regeneron Pharmaceuticals makes up approximately 1.1% of World Investment Advisors LLC's portfolio, making the stock its 8th biggest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of REGN. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 10 shares during the period. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Finally, Family Firm Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $32.03 during midday trading on Thursday, hitting $740.97. The company had a trading volume of 923,616 shares, compared to its average volume of 555,558. The stock has a market cap of $81.43 billion, a price-to-earnings ratio of 19.13, a PEG ratio of 3.00 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company's 50 day simple moving average is $860.87 and its 200 day simple moving average is $1,007.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

Analyst Ratings Changes

Several research analysts have commented on REGN shares. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating for the company in a report on Tuesday, October 22nd. Leerink Partners reiterated a "market perform" rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price objective for the company. Finally, Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $1,099.90.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.